EGFR and non-small cell lung carcinoma: In addition, our data indicate that ST7612AA1 can significantly inhibit in vitro the proliferation of NSCLC cell lines bearing wild type EGFR (and mutant KRAS), such as NCI-H460, as well as a secondary (T790M) EGFR mutation, which is known to confer resistance to tyrosine kinase inhibitors [23], such as NCI-H1975.